Brian Stahl, MD
Ophthalmology · Beavercreek, OHNPI 1942202700
Payments from drug & device makers
What this record shows
This record is dominated by charitable contributions: $2,521 of the $2,780 with a category attached, or 90.7%. Microsurgical Technology, Inc. accounts for 90.7% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $2,578, more than ten times the $61 reported in 2019.
Across 12 payments — averaging $231.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Microsurgical Technology, Inc.$3K
- Alcon$179
- AbbVie$43
- Oyster Point Pharma, Inc.$21
- Johnson & Johnson Surgical Vision, Inc.$16
What the payments were for
- Food & beverage$2599%
- Charitable contribution$2,52191%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Microsurgical Technology, Inc. | 1 | $2,521 |
| Alcon | 7 | $179 |
| AbbVie | 2 | $43 |
| Oyster Point Pharma, Inc. | 1 | $21 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $16 |
How this compares
$2,780 in reported general payments places this provider in the 70th percentile of 640 ophthalmology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 36 | $16,809 |
| RocklatanNetarsudil Mesylat/Latanoprost | 13 | $9,293 |
| Brimonidine Tartrate | 77 | $6,866 |
| Prednisolone Acetate | 83 | $2,668 |
| Latanoprost | 278 | $2,395 |
| Ketorolac Tromethamine | 79 | $1,763 |
| Difluprednate | 20 | $1,739 |
| MoxifloxacinMoxifloxacin Hcl | 52 | $1,541 |
| Gatifloxacin | 16 | $778 |
| Timolol Maleate | 76 | $738 |
| Fluorometholone | 14 | $540 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 27 | $276 |
| Dorzolamide Hcl | 12 | $221 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 17 | $69 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan | $43 | $16,80936 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 640 ophthalmology providers in Ohio.
Other ophthalmology in Beavercreek
- Peter KaiserCleveland$1.5M
- Gregory EippertMentor$813K
- Robert OsherCincinnati$720K
- Justis EhlersCleveland$639K
- Lawrence SingermanBeachwood$599K
- Darrell WhiteWestlake$587K
- Alice EpitropoulosColumbus$531K
- Amy MillerDayton$526K
- Sunil SrivastavaCleveland$508K
- William WileyCleveland$479K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.